“Higher throughput testing and higher levels of automation are becoming an increasingly pressing need for laboratories. The drawbacks typical of manual testing, such as long hands-on time, inconsistent assay performance or issues with traceability, will become a part of the past,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. ”The RoboBlot Non-Heated system has been brought to the market to answer the needs of laboratories looking for a high-throughput blot strip testing solution with minimal hands-on time. This system’s design will transform workflow from tedious manual or semi-automatic work into completely automated testing.”
RoboBlot Non-Heated extends the range of automation solutions already offered by Fujirebio Europe N.V. for the widely used INNO-LIA Score assay portfolio, and it allows for an even more customized fit with individual laboratory needs. Other automation solutions for this portfolio include the Auto-LIA™ 48, AUTOBLOT 3000 and TENDIGO®.
More information about RoboBlot Non-Heated can be found here.
A heated version of RoboBlot is being evaluated for use with Fujirebio’s reverse hybridization INNO-LiPA® molecular assays.
Please contact your local sales representative for the availability of these products in your country.
About Bee Robotics Ltd.
Founded in 1999, Bee Robotics Ltd. is a privately-owned company based in North Wales that has established a world-wide reputation as a leader in the field of design and manufacture of advanced liquid handling robotic solutions for laboratory automation. Today Bee Robotics Ltd. employs a highly skilled core team specialized in electronic, mechanical, robotics and software engineering that is involved from hardware and software design and prototyping, to development and manufacturing laboratory solutions.
Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.
Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.
Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.
Fujirebio is today a member of Miraca Group (Miraca Holdings Inc. listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1.200 people in Asia, Europe and America.